Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,561 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bicalutamide ('Casodex') 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme.
Wirth M, Tyrrell C, Delaere K, Sánchez-Chapado M, Ramon J, Wallace DM, Hetherington J, Pina F, Heyns C, Borchers T, Morris T, Armstrong J; 'Casodex' Early Prostate Cancer Trialists' Group. Wirth M, et al. Among authors: morris t. Prostate Cancer Prostatic Dis. 2005;8(2):194-200. doi: 10.1038/sj.pcan.4500799. Prostate Cancer Prostatic Dis. 2005. PMID: 15931272 Clinical Trial.
Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
Miller K, Moul JW, Gleave M, Fizazi K, Nelson JB, Morris T, Nathan FE, McIntosh S, Pemberton K, Higano CS. Miller K, et al. Among authors: morris t. Prostate Cancer Prostatic Dis. 2013 Jun;16(2):187-92. doi: 10.1038/pcan.2013.2. Epub 2013 Feb 5. Prostate Cancer Prostatic Dis. 2013. PMID: 23381694 Clinical Trial.
Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Fradet Y, Egerdie B, Andersen M, Tammela TL, Nachabe M, Armstrong J, Morris T, Navani S. Fradet Y, et al. Among authors: morris t. Eur Urol. 2007 Jul;52(1):106-14. doi: 10.1016/j.eururo.2007.01.031. Epub 2007 Jan 16. Eur Urol. 2007. PMID: 17270340 Clinical Trial.
Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia.
Tyrrell CJ, Payne H, Tammela TL, Bakke A, Lodding P, Goedhals L, Van Erps P, Boon T, Van De Beek C, Andersson SO, Morris T, Carroll K. Tyrrell CJ, et al. Among authors: morris t. Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):476-83. doi: 10.1016/j.ijrobp.2004.03.022. Int J Radiat Oncol Biol Phys. 2004. PMID: 15380582 Clinical Trial.
Is the efficacy of hormonal therapy affected by lymph node status? data from the bicalutamide (Casodex) Early Prostate Cancer program.
Iversen P, Wirth MP, See WA, McLeod DG, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Lundmo P, Tammela TL, Johansson JE, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Iversen P, et al. Among authors: morris t. Urology. 2004 May;63(5):928-33. doi: 10.1016/j.urology.2004.02.011. Urology. 2004. PMID: 15134983 Clinical Trial.
Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years.
Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Wirth MP, et al. Among authors: morris t. J Urol. 2004 Nov;172(5 Pt 1):1865-70. doi: 10.1097/01.ju.0000140159.94703.80. J Urol. 2004. PMID: 15540740 Clinical Trial.
1,561 results